{"id":"hs-20137","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297389","moleculeType":"Small molecule","molecularWeight":"421.44"},"_fixedAt":"2026-03-30T13:44:31.010789","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HS-20137 targets FGFR kinase activity to inhibit downstream proliferation and survival pathways in tumors with FGFR alterations. By selectively blocking FGFR signaling, the drug aims to suppress tumor growth in cancers driven by FGFR mutations, amplifications, or fusions.","oneSentence":"HS-20137 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:58.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (Phase 3 development)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT06844799","phase":"PHASE3","title":"A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-06-10","conditions":"Moderate-to-severe Plaque Psoriasis","enrollment":720}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2026 Mar 22","pmid":"41866443","title":"HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study.","journal":"Dermatology and therapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HS-20137","genericName":"HS-20137","companyName":"Hansoh BioMedical R&D Company","companyId":"hansoh-biomedical-r-d-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-20137 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}